AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
• Biofrontera sells Xepi license to Pelthos for up to $10M • Proceeds bolster cash position, expected to fund to profitability • Supports growth of PDT platform and expansion of Ameluz into new indications • Transaction bolsters Biofrontera's financial position, enabling further development • Milestone payments of up to $6M contingent on sales performance • Expected to fund Biofrontera's commercial and R&D activities.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet